Cellzome AG bucked the gloomy venture market and raised €30 million in its third round of financing. The company, spun off from the European Molecular Biology Laboratory in Heidelberg in May 2000, aims to speed and streamline drug discovery through better understanding the role of cellular pathways in human diseases. (BioWorld Today)